Jia Jie Biomedical Co., Ltd.(TW:4109)
NT$10.25+0.05 (+0.49%)
TW:4109
Jia Jie Biomedical Co., Ltd. financials statements
NT$10.25
At close:+0.05 (+0.49%)
Jia Jie Biomedical Co., Ltd. (4109) Ratios
Jia Jie Biomedical Co., Ltd. Ratios
TW:4109's free cash flow for Q2 2026 was NT$-14.53M. For the 2026 fiscal year, TW:4109's free cash flow was decreased by NT$-3.01M and operating cash flow was NT$-11.52M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.36 | 2.98 | 1.30 | 4.31 | 4.15 |
| Quick Ratio | 3.20 | 2.77 | 1.22 | 3.95 | 3.90 |
| Cash Ratio | 1.74 | 0.97 | 1.05 | 1.71 | 2.10 |
| Solvency Ratio | 0.39 | 1.85 | 0.46 | 0.14 | 0.22 |
| Operating Cash Flow Ratio | 0.12 | 0.38 | -0.01 | -0.12 | 0.05 |
| Short-Term Operating Cash Flow Coverage | 0.42 | 147.82 | -0.06 | -74.39 | 26.34 |
| Net Current Asset Value | NT$ 399.59M | NT$ 225.25M | NT$ 94.61M | NT$ 237.22M | NT$ 253.81M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.01 | 0.05 | 0.00 | 0.01 |
| Debt-to-Equity Ratio | 0.03 | 0.01 | 0.07 | 0.00 | 0.01 |
| Debt-to-Capital Ratio | 0.03 | 0.01 | 0.07 | 0.00 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.12 | 1.11 | 1.35 | 1.12 | 1.13 |
| Debt Service Coverage Ratio | 0.21 | 247.18 | 2.15 | 44.82 | 81.00 |
| Interest Coverage Ratio | 2.56 | 51.83 | -190.23 | -46.68 | 82.87 |
| Debt to Market Cap | 0.03 | 0.00 | 0.05 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.44 | 0.09 | 0.87 | 0.04 | 0.06 |
| Net Debt to EBITDA | -13.35 | -0.43 | -1.72 | -10.05 | -8.99 |
| Profitability Margins | |||||
| Gross Profit Margin | 30.97% | 32.28% | 35.35% | 36.67% | 34.55% |
| EBIT Margin | 0.15% | 42.10% | 44.15% | -1.44% | 2.21% |
| EBITDA Margin | 3.76% | 45.05% | 48.47% | 3.81% | 7.66% |
| Operating Profit Margin | 0.15% | 6.19% | -19.89% | -1.66% | 2.08% |
| Pretax Profit Margin | 12.33% | 41.98% | 44.04% | -1.47% | 2.18% |
| Net Profit Margin | 10.35% | 39.36% | 43.32% | -1.72% | 2.20% |
| Continuous Operations Profit Margin | 10.74% | 40.25% | 44.18% | -2.03% | 2.10% |
| Net Income Per EBT | 83.96% | 93.74% | 98.36% | 116.88% | 100.95% |
| EBT Per EBIT | 8431.55% | 678.74% | -221.37% | 88.72% | 104.65% |
| Return on Assets (ROA) | 2.66% | 14.26% | 10.20% | -0.54% | 0.52% |
| Return on Equity (ROE) | 2.98% | 15.88% | 13.77% | -0.61% | 0.59% |
| Return on Capital Employed (ROCE) | 0.04% | 2.43% | -6.15% | -0.57% | 0.54% |
| Return on Invested Capital (ROIC) | 0.03% | 2.33% | -5.75% | -0.57% | 0.52% |
| Return on Tangible Assets | 2.77% | 15.03% | 10.35% | -0.56% | 0.53% |
| Earnings Yield | 2.68% | 9.68% | 9.60% | -0.43% | 0.46% |
| Efficiency Ratios | |||||
| Receivables Turnover | 9.50 | 10.81 | 18.73 | 16.74 | 9.92 |
| Payables Turnover | 13.87 | 29.92 | 19.09 | 19.77 | 13.74 |
| Inventory Turnover | 12.11 | 14.85 | 8.72 | 7.55 | 7.63 |
| Fixed Asset Turnover | 0.99 | 1.19 | 0.74 | 0.70 | 0.55 |
| Asset Turnover | 0.26 | 0.36 | 0.24 | 0.32 | 0.24 |
| Working Capital Turnover Ratio | 1.53 | 3.24 | 1.93 | 1.27 | 0.87 |
| Cash Conversion Cycle | 42.26 | 46.14 | 42.25 | 51.67 | 58.04 |
| Days of Sales Outstanding | 38.43 | 33.76 | 19.49 | 21.81 | 36.78 |
| Days of Inventory Outstanding | 30.15 | 24.58 | 41.88 | 48.32 | 47.82 |
| Days of Payables Outstanding | 26.32 | 12.20 | 19.12 | 18.47 | 26.56 |
| Operating Cycle | 68.58 | 58.34 | 61.37 | 70.13 | 84.60 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.18 | 0.44 | -0.05 | -0.10 | 0.05 |
| Free Cash Flow Per Share | -0.53 | 0.25 | -0.15 | -0.30 | 0.03 |
| Dividend Paid and CapEx Coverage Ratio | 0.15 | 0.64 | -0.52 | -0.49 | 2.88 |
| Capital Expenditure Coverage Ratio | 0.25 | 2.26 | -0.52 | -0.49 | 2.88 |
| Operating Cash Flow Coverage Ratio | 0.40 | 5.05 | -0.06 | -2.35 | 0.83 |
| Operating Cash Flow to Sales Ratio | 0.04 | 0.08 | -0.01 | -0.03 | 0.02 |
| Free Cash Flow Yield | -3.41% | 1.13% | -0.87% | -2.09% | 0.25% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 36.05 | 10.33 | 10.42 | -232.52 | 217.33 |
| Price-to-Sales (P/S) Ratio | 3.87 | 4.07 | 4.51 | 4.00 | 4.78 |
| Price-to-Book (P/B) Ratio | 1.12 | 1.64 | 1.43 | 1.42 | 1.28 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -29.28 | 88.37 | -114.66 | -47.75 | 406.35 |
| Price-to-Operating Cash Flow Ratio | 88.02 | 49.26 | -334.66 | -144.88 | 265.20 |
| Price-to-Earnings Growth (PEG) Ratio | -0.45 | 0.35 | -0.00 | 1.15 | -1.92 |
| Enterprise Value Multiple | 89.64 | 8.60 | 7.59 | 94.91 | 53.43 |
| Enterprise Value | 1.64B | 2.08B | 1.22B | 1.15B | 992.72M |
| EV to EBITDA | 89.64 | 8.60 | 7.59 | 94.91 | 53.43 |
| EV to Sales | 3.37 | 3.87 | 3.68 | 3.62 | 4.09 |
| EV to Free Cash Flow | -25.49 | 84.15 | -93.46 | -43.17 | 347.84 |
| EV to Operating Cash Flow | 76.62 | 46.91 | -272.79 | -131.01 | 227.01 |
| Tangible Book Value Per Share | 13.53 | 12.75 | 11.80 | 10.18 | 10.28 |
| Shareholders’ Equity Per Share | 13.89 | 13.22 | 11.77 | 10.10 | 10.21 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.13 | 0.04 | -0.00 | -0.38 | 0.04 |
| Revenue Per Share | 4.00 | 5.34 | 3.74 | 3.57 | 2.73 |
| Net Income Per Share | 0.41 | 2.10 | 1.62 | -0.06 | 0.06 |
| Tax Burden | 0.84 | 0.94 | 0.98 | 1.17 | 1.01 |
| Interest Burden | 84.32 | 1.00 | 1.00 | 1.02 | 0.99 |
| Research & Development to Revenue | 0.01 | 0.01 | 0.03 | 0.03 | 0.01 |
| SG&A to Revenue | 0.29 | 0.25 | 0.53 | 0.38 | 0.34 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.36 | 0.20 | -0.03 | 1.88 | 0.83 |
Currency in TWD
